BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Accounts Payable

Track Freeline Therapeutics Holdings plc's accounts payable ($7.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$7.78M
21.88% YoYΔ $-2.18M vs prior year quarter

Peer average

Loading

Freeline Therapeutics Holdings plc Accounts Payable History

Loading

Freeline Therapeutics Holdings plc vs. peers: Accounts Payable Comparison

Loading

Freeline Therapeutics Holdings plc Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc (FRLN) currently reports a accounts payable of $7.8M as of September 2023. That compares with $10M in the prior-year period — down 21.9% year over year. Use the charts on this page to explore Freeline Therapeutics Holdings plc's accounts payable history and peer comparisons.

Freeline Therapeutics Holdings plc's accounts payable decreased from $10M to $7.8M — a 21.9% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Freeline Therapeutics Holdings plc reported $7.8M in accounts payable as of September 2023. That compares with $10M in the prior-year period — down 21.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $7.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Freeline Therapeutics Holdings plc, and consider following FRLN for alerts when major investors trade the stock.

Freeline Therapeutics Holdings plc is classified in the Healthcare sector. On accounts payable, it currently shows $7.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRLN with unrelated industries.